Technology

IIIT-D Develops AI Model To Repurpose Existing Drugs To Treat COVID19

New Delhi: Indraprastha Institute of Data Expertise (IIIT-Delhi) on Sunday stated it has developed an Synthetic Intelligence (AI) mannequin for drug repositioning within the remedy of Covid-19.

Which means that as a substitute of manually going by way of ever out there drug and checking its effectiveness in opposition to Covid-19 (which is a painstakingly lengthy course of), one can now depend on AI to hurry issues up and discover us the medicine which have the very best likelihood of success in opposition to the illness.

Some well-known examples of repositioned medicine are Hydroxychloroquine (HCQ), Dexamethasone, Remdesivir, Avifavir/Favipiravir and so forth.

Sime lesser-known medicine which can be on trial embody Ribavirin, Umifenovir, Sofosbuvir and a number of other antiretrovirals.

The database of medicine (drugbank.ca) lists greater than 100 accredited antivirals. Making an attempt out all of them in scientific trials will not be potential; it is going to be costly each financially and when it comes to time – a luxurious we can’t afford.

“Therefore, we propose to use AI to prune this massive database and select a handful (5 to 10) of drugs that have better chances of succeeding. This would allow more concerted effort/trials on this handful of prospective treatment regimes,” IIIT Delhi stated in a press release.

In easy phrases, the AI mannequin computes the similarity between the chemical constructions of the medicine and the similarity between the genomic constructions of present viruses and the novel Coronavirus.

The mannequin then seems on the historic details about the efficacy of the medicine on totally different viruses; it selects related medicine (based mostly on chemical construction) which were profitable in treating viruses which have a genomic construction near that of the novel Coronavirus.

The AI mannequin that would show to be an indispensable instrument within the battle in opposition to Covid-19 has been the results of collaboration between IIIT Delhi, IPGME&R Kolkata and INRIA, Saclay, Paris, France.

(IANS)

Additionally Learn: Russia 1st Nation To End Human Trials For Covid-19 Vaccine

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button